Naing, A., Almhanna, K., Baranda, J. C., Galvao, V., Garralda, E., Calvo, E., Dongen, M. V., Eskens, F., Cohen, J., Beller, T., Menas, F., Zhu, C., Tada, K., Guillemin-Paveau, H., Koch, V., Huh, W., Abbadessa, G., Perez, R. P., Gutierrez, M. (2025). Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2572